FDA says Elanco's Pradalex ads misbrand the livestock antibiotic by claiming first-line use and "all relevant pathogen" coverage.
What happened
FDA's Center for Veterinary Medicine reviewed Elanco's promotional materials for Pradalex (pradofloxacin injection) — a print ad, a detail aid, a cattle technical manual, a product overview presentation, a promotional video and product webpages. FDA found the materials false or misleading because they recommend Pradalex as a "first-pull" (first) treatment, say it works against "all relevant" cattle and swine respiratory pathogens, and make unclear "2x/3x the power in less than half the time" comparisons based on laboratory bacterial-kill data rather than clinical outcomes. No inspection is mentioned; the review was of the communications themselves.
What FDA found
The ads call Pradalex "recommended" or an "ideal choice" for first-pull treatment, but the approved label says to use it only after considering other non-fluoroquinolone options.
FD&C Act 502(a), 502(n), 201(n) [21 U.S.C. 352(a), 352(n), 321(n)]; 21 CFR 202.1(e)(5)The ads say Pradalex is effective against "all relevant" cattle and swine respiratory pathogens, although it is not approved for some of them, such as Bibersteinia trehalosi and Actinobacillus pleuropneumoniae.
FD&C Act 502(a), 502(n), 201(n); 21 CFR 202.1(e)(5)The print ad's "2x the power in less than half the time" implies it treats respiratory disease generally and implies treatment speed from a lab kill-rate study that the study itself says cannot be extended to clinical results.
FD&C Act 502(a), 502(n), 201(n); 21 CFR 202.1(e)(5)Statements about "3x the power" and "2x the power" are unclear because "power" is undefined and the comparison is to no other drug or to only one other drug.
FD&C Act 502(a), 502(n), 201(n); 21 CFR 202.1(e)(5)The claims may promote extralabel use of Pradalex in food-producing animals, which the label says federal law prohibits.
21 CFR 530.4Selling a misbranded animal drug in interstate commerce is a prohibited act.
FD&C Act 301(a) [21 U.S.C. 331(a)]
What FDA wants
Within 15 working days, Elanco must send a written response listing every Pradalex promotional communication with these kinds of claims and explaining how it will stop using them or stop distributing the drug. If Elanco believes there is no violation, it must give its reasoning and supporting information in the same timeframe.
Who should pay attention
- animal health companies that advertise prescription veterinary drugs
- veterinarians and livestock producers choosing antibiotic treatment
- reviewers who check promotional materials against approved labels
This is a summary. Read the original letter on fda.gov.